(S1 (S (NP (NP (NN 11beta-hydroxysteroid) (NN dehydrogenase) (NN type) (CD 1)) (: :) (NP (NP (DT a) (JJ tissue-specific) (NN regulator)) (PP (IN of) (NP (NN glucocorticoid) (NN response)))) (. .))))
(S1 (S (S (NP (NP (NN 11beta-hydroxysteroid) (NN dehydrogenase) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN 11beta-HSD1)) (-RRB- -RRB-))) (VP (VBZ interconverts) (NP (NP (JJ inactive) (NN cortisone)) (CC and) (NP (JJ active) (NN cortisol))))) (. .)))
(S1 (S (SBAR (IN Although) (FRAG (JJ bidirectional))) (, ,) (ADVP (FW in) (FW vivo)) (NP (PRP it)) (VP (VBZ is) (VP (VBN believed) (S (VP (TO to) (VP (VB function) (PP (IN as) (NP (DT a) (NN reductase) (VBG generating) (JJ active) (NN glucocorticoid))) (PP (IN at) (NP (DT a) (JJ prereceptor) (NN level))))))) (, ,) (S (VP (VBG enhancing) (NP (NN glucocorticoid) (NN receptor) (NN activation))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN review))) (, ,) (NP (PRP we)) (VP (VBP discuss) (NP (NP (CC both) (DT the) (ADJP (ADJP (JJ genetic)) (CC and) (ADJP (JJ enzymatic))) (NN characterization)) (PP (IN of) (NP (NN 11beta-HSD1)))) (, ,) (PP (RB as) (RB well) (IN as) (S (VP (VBG describing) (NP (NP (PRP$ its) (NN role)) (PP (IN in) (NP (NP (NN physiology)) (CC and) (NP (NN pathology))))) (PP (IN in) (NP (DT a) (JJ tissue-specific) (NN manner)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ molecular) (NN basis)) (PP (IN of) (NP (NP (NN cortisone) (NN reductase) (NN deficiency)) (, ,) (NP (NP (DT the) (JJ putative) (`` ``) (NP (NN 11beta-HSD1) (JJ knockout) (NN state)) ('' '')) (PP (IN in) (NP (NNS humans)))) (, ,)))) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN defined)))) (CC and) (VP (VBZ is) (VP (VBN caused) (PP (IN by) (NP (NP (JJ intronic) (NNS mutations)) (PP (IN in) (NP (NN HSD11B1))) (SBAR (WHNP (WDT that)) (S (VP (VBP decrease) (NP (NN gene) (NN transcription)) (PP (ADVP (RB together)) (IN with) (NP (NP (NNS mutations)) (PP (IN in) (NP (NP (NN hexose-6-phosphate) (NN dehydrogenase)) (, ,) (NP (NP (DT an) (NN endoluminal) (NN enzyme)) (SBAR (WHNP (WDT that)) (S (VP (VBZ provides) (NP (NP (VBN reduced) (NN nicotinamide-adenine) (NN dinucleotide) (NN phosphate)) (PP (IN as) (NP (NN cofactor))) (PP (TO to) (NP (NN 11beta-HSD1)))) (S (VP (TO to) (VP (VB permit) (NP (NN reductase) (NN activity)))))))))))))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP speculate) (SBAR (IN that) (S (NP (NP (JJ hexose-6-phosphate) (NN dehydrogenase) (NN activity)) (CC and) (NP (ADVP (RB therefore)) (VBN reduced) (JJ nicotinamide-adenine) (NN dinucleotide) (NN phosphate) (NN supply))) (VP (MD may) (VP (VB be) (ADJP (JJ crucial) (PP (IN in) (S (VP (VBG determining) (NP (NP (DT the) (NN directionality)) (PP (IN of) (NP (NN 11beta-HSD1) (NN activity)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Therapeutic) (NN inhibition)) (PP (IN of) (NP (NN 11beta-HSD1) (NN reductase) (NN activity))) (PP (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN obesity)) (CC and) (NP (DT the) (JJ metabolic) (NN syndrome)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (NN glaucoma)) (CC and) (NP (NN osteoporosis)))) (, ,))) (VP (VBZ remains) (NP (DT an) (JJ exciting) (NN prospect)))) (. .)))
